# DrugRepo: A novel approach to repurpose a huge collection of compounds based on chemical and genomic features

Yinyin Wang[1], Jehad Aldahdooh[1], Yingying Hu[1], Hongbin Yang[2], Markus Vähä-Koskela[3], Jing Tang[1*], Ziaurrehman Tanoli[1,4*]

**Affiliation:** 1) Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Finland; 2) Department of Chemistry, University of Cambridge, Cambridge, UK; 3) Institute for Molecular Medicine Finland, University of Helsinki, Finland; 4) BioICAWtech, Helsinki, Finland

*Correspondence: jing.tang@helsinki.fi, zia.rehman@helsinki.fi

## ABSTRACT

Drug development process consumes 9-12 years and approximately one billion US dollars in terms of costs. Due to high finances and time costs required by the traditional drug discovery paradigm, repurposing of the old drugs to treat cancer as well as rare diseases is becoming popular. Computational approaches are mainly data-driven and involve a systematic analysis of different data types leading to the formulation of repurposing hypotheses. In this study, we present a novel scoring algorithm based on chemical and genomic data types to repurpose a huge collection of compounds for 674 cancer types and other diseases. The data types used to design the scoring algorithm are chemical structures, drug-target interactions (DTI), pathways, and disease-gene associations. The repurpose scoring algorithm is strengthened by integrating the most comprehensive manually curated datasets for each data type. More than 100 of our repurposed compounds can be matched with ongoing studies at clinical trial (https://clinicaltrials.gov/). Our analysis is supported by a web tool available at: http://drugrepo.org/.

## KEYWORDS

Drug discovery, drug repurposing, computational drug repurposing, drug-target interactions, disease-gene associations, protein-protein interactions

## 1. INTRODUCTION

The average cost of developing a new drug is billions of dollars and it takes about 9–12 years to bring a new drug to the market [1]. Finding new uses for approved drugs has become a major alternative strategy for the pharmaceutical industry. This practice usually referred to as drug repositioning or drug repurposing, is highly attractive because of its potential to speed up the process of drug development, reduce costs, and provide treatments for unmet medical needs [2]. In this regard, compounds that have passed through phases I or II in the drug discovery pipeline but never made it to the market due to efficacy issues carry great potential for drug repositioning. Traditionally, drug repurposing success stories have mainly resulted from largely opportunistic and serendipitous findings [3]. For example, sildenafil citrate was originally developed as an antihypertensive drug but later repurposed by Pfizer and marketed as Viagra for the treatment of erectile dysfunction based on retrospective clinical experience, leading to massive worldwide sales. Other examples of such drug repositioning include cancer drugs: crizotinib, sorafenib, azacitidine and decitabine, all of which failed to reach the markets in their original indications, yet now are important tools in the treatment of various types of cancers [4].

Over the recent years, various computational resources have been developed to support systematic drug repurposing. Popular information sources for *in-silico* drug repurposing include, for instance, electronic health records, genome-wide association analyses or gene expression response profiles, pathway mappings, compound structures, target binding assays and other phenotypic profiling data [3]. Several systematic review articles on the use of computational repurposing approaches are available that cover machine learning (ML) algorithms [5][6][7]. Several databases directly support *in-silico* drug repurposing including Drug Repurposing Hub [8], repoDB [9] and RepurposeDB [10]. On the other hand, there are hundreds of databases that can indirectly support drug repurposing [7][11]. However, these databases provide experimentally tested indications only for a limited number of investigational or approved compounds and ignored the huge number of preclinical compounds that could be potential candidates for drug repurposing. Drug target profiles for approximately 2 millions of such preclinical compounds are available at ChEMBL[12] and other databases.

Drug-target interactions (DTI), meaning the target molecules each compound binds to, and the relative binding strength and impact on cellular functions, lie at the heart of drug discovery and repositioning. Several artificial intelligence (AI) methods for drug repurposing are based on DTIs as well as chemical structural similarities [13][14][15]. However, these methods are

applied only on selected set of compounds resulting in limited prediction outcomes [13]. Computational approaches are primarily data-driven and involve a systematic analysis of several components (or data types) before suggesting a repurposed indication. These components may include chemical structures, adverse event profiles, compound-target interactions, pathways, disease-gene associations, genomic, proteomic, and transcriptomic information. The drug repurposing methods can be developed based on individual or combination of any of these components.

In this study, we propose DrugRepo (http://drugrepo.org/), a novel scoring algorithm that can effectively repurpose hundreds of thousands of compounds based on three components, 1) overlapping compound-targets score (OCTS), 2) structure similarity score based on tanimoto coefficient (TC), and 3) compound-disease score (CDS). The DrugRepo score is computed between the approved drug (for a particular disease) and candidate compound and is the average of the three component scores. Approved indications for **674** diseases and **1,092** compounds are collected from https://clinicaltrials.gov/. To explore the translational impact of DrugRepo, we cross-referenced candidate compounds with completed clinical trials at https://clinicaltrials.gov/. Using this approach, we observed that 186 compounds are explored in different clinical studies across nine cancer types. We also compared our candidate compounds with the predicted compound disease relationships at the Comparative Toxicogenomic Database (CTD) [16], and found a statistically significant overlap. These promising findings demonstrate the versatility of DrugRepo. Our new tool provides a quick and effective scoring method for drug repurposing.

## 2. MATERIALS

Several types of data are integrated in this analysis e.g., approved drug indications, compound-target profiles, disease-gene associations, and protein-protein interaction (PPI) networks. These datasets are consequently explained in the following subsections.

### 2.1. Approved drug indications

Approved drug indications are extracted from clinical trials database (https://clinicaltrials.gov/), as it is the most up to date repository for drug indications as well as clinical phases for the compounds. However, the data provided by clinical trials is not well structured and doesn't provide standard naming conventions or identifiers for the compounds and diseases. We therefore utilized a semi-automated approach to extract drug-disease

indications, assigned UML-CUI and standard InChIKey identifiers for drugs and diseases respectively. The standard InChIKey mapping is performed using PubChem python client (https://pubchempy.readthedocs.io/en/latest/), whereas UML-CUIs are assigned to the diseases using disease annotations provided by DisGeNET [17]. Finally, we extracted data for 674 diseases, 1,092 drugs, and 3,868 approved drug indications as shown in Supplementary file 1.

### 2.2. Compound-target profiles

Non-overlapping compound-target profiles are extracted from the five most comprehensive (and manually curated) databases namely; ChEMBL [18], BindingDB [19], GtopDB [20], DrugBank [21] and DGiDB [22]. The compound identifiers in these databases are mapped into standard InChIKeys and SMILES using UniChem [23] and PubChem [24] respectively, whereas identifiers for target proteins are mapped to UniProt identifiers [25]. The number of combined non-overlapping compounds from the five databases exceeds **2M** with approximately **15,000** targets. These comprehensive datasets are extracted using application programmable interfaces (APIs), standalone text files, and SQL dumps. The first three databases, ChEMBL, BindingDB and GtopDB provide quantitative bioactivity data, such as measurements in terms of $IC_{50}$, $K_d$, and $K_i$, whereas DrugBank and DGiDB contain unary but experimentally verified compound-target interactions. In addition to active or potent compound-target profiles in ChEMBL, BindingDB and GtopDB, there exists a big proportion of in-active compound-target profiles (concentration > 10,000 nM). These in-active compound-target profiles could jeopardize the analysis in the proposed research. Therefore, in this analysis, we considered only potent compound-target profiles (concentration is <=1000 nM) [26]. Hence, we left with **788,078** compounds and **8,754** protein targets. Potent target profiles for these ~0.8M compounds are already integrated and publicly available in MICHA (https://micha-protocol.org/) [27].

### 2.3. Disease-gene associations and PPI networks

To support the large-scale drug repurposing, we integrated manually curated disease-gene associations from DisGeNET [17]. There are 9,703 genes, 11,181 diseases and 84,038 associations. These curated disease-gene associations are provided in Supplementary file 2.

Protein-protein interactions (PPI) networks were extracted from a manually curated human interactome including 16,677 proteins and 243,603 PPIs [28].

## 3. METHODS

There are 788,078 compounds for which there exists at least one potent target (concentration is ≤1000 nM) in any of the five DTI databases. We call these agents candidate compounds to be repurposed. For each candidate compound, the DrugRepo score is calculated as the average of three component scores, OCTS, TC, CDS, which in turn are derived by comparing each candidate compound to 1,092 approved drugs (**Figure 1**). Because the number of calculated scores (788,078 x 1092) is too big for the web portal to handle smoothly, we considered only those cases where structural similarity between approved drug and candidate compound is ≥ 0.2. This way, we were left with 2,207,367 scores.




***Figure 1****:The DrugRepo pipeline starts by the user selecting a particular disease. There are 0.8M candidate compounds in DrugRepo that can be repurposed for 674 diseases. At first, the pipeline finds approved drug(s) for the selected disease and searches for structurally similar compounds. In this step, the Tanimoto coefficient (TC) describes the structural similarity between molecular fingerprints (ECFP4) of approved and candidate compounds. A threshold is used to favor similar molecular structures. The second step is to compute DTI profiles for candidate compounds and approved drugs. Here, the OCTS is the score based on overlapping DTIs between approved and candidate compounds. The third step is to compute the compound-disease score (CDS). The CDS is the average of the minimum distances in the PPI networks between target molecules and molecules known to be associated with the selected disease. The average distance is normalized to 0-1. Finally, the DrugRepo score is calculated as the average of the three component scores. The higher the DrugRepo score between the approved drug and the candidate compound, the higher the possibility of repurposing the compound for a particular disease.*

The OCTS between approved and candidate compounds are computed using equation 1. The OCTS ranges from 0-1 and represents the proportion of targets shared between an approved drug and the candidate compounds. Candidate compounds sharing more targets with the approved drugs will have higher OCTS values.

$$OCTS = \frac{Drug_T \cap \text{Compound}_T}{\min(|Drug_T|, |\text{Compound}_T|)} \quad (1)$$

Where $Drug_T$ $and$ $\text{Compound}_T$ are the sets of potent targets for a pair of approved drug and candidate compound respectively. Similarly, $|Drug_T|$ $and$ $|\text{Compound}_T|$ are the total number of targets associated with approved drug and the candidate compound respectively.

Compound-target profiles are extracted from five databases. The number of overlapping compounds and targets in these five databases are shown in **Figure 2A** and **Figure 2B**, respectively. As evident from **Figure 2A**, ChEMBL features the most comprehensive collection of compounds, whereas DrugBank covers a greater number of targets (**Figure 2B**). There are 483 compounds and 776 targets that are common between all five databases.

Drug repurposing is challenging because of shortcomings in data coverage. On one hand, while diseases associated with a greater number of approved drugs may have better chances of finding correctly repurposed compounds, as the number of candidate compounds will also be larger, only very few diseases are covered by a multitude of approved drugs. HIV is covered by the largest number of approved drugs (n = 103), but as shown in **Figure 2C**, more than 70% diseases have less than five approved drugs. On the other hand, lack of drug-target-interactions is also a hurdle as it limits matching of compounds by putative mechanism of action. Indeed, most approved drugs have less than 30 targets (**Figure 2D**). To compensate for the shortage of approved drugs and drug-target-interactions, we incorporated two additional components in the DrugRepo pipeline: the Tanimoto coefficient (TC), which is a structural similarity score, and the compound-disease score (CDS), which ranks new compounds based on how closely their target spaces match with the target proteins that are associated with the disease.

The Tanimoto coefficient (TC) is used to measure structural similarities between molecular ECFP4 fingerprints of approved and candidate compound for a particular disease. The fingerprints are the bit strings denoting the presence or the absence of chemical substructures, and they are calculated using RDKit [29].

$$\text{TC} = \frac{N_{AC}}{N_A + N_C - N_{AC}} \quad (2)$$

Where $N_A$ $and$ $N_C$ are the number of sub-structures present in the approved drug and candidate compound respectively, and $N_{AC}$ are number of common sub-structures found in

both approved drug and the candidate compound. The value of TC is between range 0-1 and constitutes the second component of DrugRepo.




***Figure 2**: (A) Number of overlapping compounds across five databases. (B) Number of overlapping targets between five databases. (C) Distribution of diseases across 1092 approved drugs. (D)Target coverage across 1092 approved drugs.*

The compound-disease score (CDS) is measured by averaging the minimum distances in PPI networks between potent targets of the candidate compound and genes known to be associated with the disease as shown in equation 3. Curated disease-gene associations were extracted from DisGeNET for the 674 diseases use in this analysis. There are 22,399 non-zero CDS values.

$$CDS(C_G, D_G) = \frac{1}{|D_G| + |C_G|} \sum_{i,j} min\ d(g_i, g'_j) \qquad (3)$$

Where $C_G = (g_{1,} g_{2,} \ldots)$ is the set of gene targets for candidate compound and $D_G = (g'_1, g'_2 \ldots)$ are the genes associated with a particular disease (acquired from DisGeNET). The average of minimum distances between $C_G\ and\ D_G$ are computed in PPI networks. The average distance is further normalized to range 0-1 using min-max normalization. Finally, the DrugRepo score is the mean of the three compound scores and has range of 0 to 1. The higher the DrugRepo score between an approved drug (for a particular disease) and a candidate compound, the greater the repurposing potential of the candidate compound for that disease.

## 4. RESULTS AND DISCUSSIONS

To explore the translational impact of DrugRepo, we evaluated our repurposed compounds using two methods i.e. 1) cross-referenced thousands of the repurposed compounds using disease-compound associations in CTD [16], 2) matched 186 compound across nine cancer

types for which either Phase I or Phase II trials have been completed or Phase III trials is ongoing.

### 4.1.Matching repurposed compounds with disease-compound associations in CTD

The Comparative Toxicogenomic Database (CTD) contains manually curated and inferred compound-disease relationships [16]. CTD associates thousands of compounds with diseases based on drug-target and disease-gene relationships. Our scoring method and the datasets are different from CTD, but the output types in DrugRepo and CTD are the same. We therefore assessed the accuracy of DrugRepo by comparing the repurposed compounds with compound-disease relationships in CTD. We downloaded disease-compound relationships from CTD at: http://ctdbase.org/downloads/;jsessionid=5DA98FA00707F8A41A59335C1CC36C47#cd. In CTD, compounds are represented by CAS identifier or compound names; and diseases are represented using Mesh ids. To make the comparison possible, we mapped compound names from CTD dataset into standard InChIKeys using PubChempy. Diseases are mapped from MESH ids into UML-CUI. There are 1,048,548 compound-disease associations in CTD, including 3,941 compounds and 6,119 diseases. Many of these compounds and disease are unable to map into standard InChIKeys and UML-CUI identifiers. We therefore skipped those cases and left with only 168,471 compound-disease associations (605 diseases and 2,598 compounds) as shown in Supplementary file 3. These associations are used to match repurposing candidate compounds by DrugRepo. The significance of matching results for overlapping compounds (for a particular disease) between DrugRepo and CTD is computed using the following equations:

$$N_{overlap} = |\, C_d \cap \, C_r|$$

$$N_{expected} \; = |C_d| * |C_r|/|C_{all}|$$

$$Sig_d = N_{overlap} - \; N_{expected}$$

Where $C_{all}$ are a set of all candidate compounds (~0.8M) in DrugRepo, $C_d$ is set of compounds associated to disease 'd' in CTD, $C_r$ is the set of repurposed compounds by DrugRepo for the same disease 'd', $N_{overlap}$ is the number of overlapping compounds between CTD and DrugRepo, $N_{expected}$ is the expected number of compounds overlapping with $C_d$ if we randomly choose the same number of compounds as $|C_r|$ from $C_{all}$, and $Sig_d$ is the

significance of matched compounds. If the significance is greater than 0, it means our repurposing is not random.

As we have ~0.8M candidate compounds and 1,092 approved drugs, this could result in huge matrix (~800M). We therefore considered only those candidate compounds which at least have 50% structural similarity with any of the approved drugs (TC >= 0.5). If $N_{overlap}$ for a particular disease is greater than $N_{expected}$, $Sig_d$ will be positive, meaning that repurposed compounds by DrugRepo are matched with CTD. Diseases with the significance score > 0 are shown in **Figure 3A** ($N_{expected}$ is shown in blue and $N_{overlap}$ with red bars). As shown in **Figure 3A**, the blue bar represents expected number of compounds, and the red bar indicates the actual number of matched compounds. Most of blue bar are less than 1, suggesting that if chosen randomly, there should be less than one candidate compound that can be matched for most of the diseases. In fact, we matched more than one correctly repurposed compound for 118 diseases (**Figure 3A**). In other words, DrugRepo shows good repurposing ability in 118 out of the 605 diseases in CTD, suggesting that our novel pipeline is effective in repurposing compounds for several diseases. As an example, for myocardial infarction for which there are 4,921 candidate compounds returned by DrugRepo, and 401 compounds by CTD. If the selection of the 4,921 compounds (from the 788,078 total candidate compounds) had been random, we would have expected an average of 2.51 matched compounds. However, we matched 15 compounds with CTD (6 folds bigger than the expected number), suggesting that the DrugRepo pipeline indeed extracts biologically relevant candidate compounds.

To investigate the effect of structural similarity on drug repurposing, we evaluated the matched repurposed compounds on 5 different thresholds (TC: 0.5, 0.6, 0.7, 0.8, 0.9). As shown in **Figure 3B**, the number of matched repurposed compounds tends to decrease with strict TC filtration on repurposed compounds as expected. However, the significance scores are also reduced, especially after TC ≥ 0.9, suggesting that high structure similarity is not a determining factor for drug repurposing. Many of the matched repurposed compounds are located at **TC >= 0.5**. On the other hand, the number of matched compounds and significance scores are relatively stable between 0.6 ≤ TC ≤ 0.7. Therefore, TC values between 0.6 to 0.7 might be optimal for drug repurposing.




***Figure 3**: (A) The circle bar for drug repurposing matching results by CTD. All the matched diseases were distributed as pie on the circle. The blue bars represent ($N_{expected}$ ) the expected number of compounds if chosen randomly while the red bar represents the actual overlap ($N_{overlap}$) between compounds in CTD and DrugRepo. (B) The Significance scores at different TC thresholds (with y-axis as thresholds and x-axis as a disease whose true positive is not 0). The significance score is represented by dot size and colour from red to blue represents number of overlapping compounds.*

We also analysed whether diseases associated with a larger number of approved drugs can have an impact on the DrugRepo scoring. As shown in Figure 4A, if a specific disease is associated with bigger number of approved drugs, then more repurposed compounds can be matched (correlation = 0.7). Similarly, the number of matched repurposed compounds ($N_{overlap}$) is also

closely associated with the significance score (**Figure 4B**). Conversely, DrugRepo performance remains poor for the diseases associated with fewer approved drugs.




***Figure 4****: The impact of significance score on number of: (A) approved drugs associated with a disease, (B) matched repurposed compounds.*

### 4.2. Matching DrugRepo candidate compounds with drugs in clinical trials

To establish if the DrugRepo pipeline enriches for compounds already tested in patients, we chose nine commonly studied cancer types to match repurposed compounds in DrugRepo with completed Phase I or Phase II or ongoing Phase III clinical trials. First, using the clinical trial API (https://clinicaltrials.gov/api/), we obtained the names of all compounds matching these criteria. We then tried to map the compound names with standard InChIKeys using PubChem's API. However, the naming convention for compounds is not yet standardized and several of compounds were not mapped and omitted from the subsequent steps.

As shown in **Figure 5A** and **5B**, we found 186 and 51 candidate compounds using structural similarity thresholds of TC >= 0.2 and TC >= 0.5, respectively. The names and identifiers of these matched compounds along with other statistics are provided in Supplementary file 4.

All these matched indications have either successfully passed phase I or phase II. There could be some candidate repurposing compounds having high DrugRepo scores but unable to match with compounds at clinical trials. This could be either due to the lack of mapping for some compounds (at clinical trials) or because only limited compounds are being tested at clinical trials. However, by looking at the matched candidate compounds, we may find suitable threshold on DrugRepo score to identify repurposing compounds.

By lowering the structural similarity threshold increased the chances of matching more repurposed compounds. **Figures 5A** and **5B** show the number of matched compounds across the nine cancer types for TC >= 0.2 and TC >= 0.5 respectively, **Figures 5C** and **5D** shows the distribution of DrugRepo scores using TC >= 0.2 and TC >= 0.5. Most of the matched candidate compounds have median DrugRepo score higher than 0.4, hence we suggest the users use at least DrugRepo >= 0.4 to get maximum repurposing compounds.




***Figure 5: (A)*** *Number of matched candidate compounds across 9 cancer types using structural similarity (TC) >=0.2,* ***(B)*** *Number of matched candidate compounds using structural similarity (TC) >=0.5,* ***(C)*** *Distribution of DrugRepo scores for macthed compounds for structural similarity (TC) >=0.2,* ***(D)*** *Distribution of DrugRepo scores for matched compounds for structural similarity (TC) >=0.5.* ***(E)*** *Distribution of compound-disease score for repurposed compounds TC >=0.2,* ***(F)*** *Distribution of compound-disease score for repurposed compounds TC >=0.5,* ***(G)*** *Distribution overlapping target profile scores between approved and repurposed compounds TC >=0.2,* ***(H)*** *Distribution overlapping target profile scores between approved and repurposed compounds TC >=0.5.*

Furthermore, we explored the effect of structural similarity on OCTS and CDS. **Figures 5E** and **5F** show that structural similarity slightly affects the OCTS thresholds but has no significant impact on compound-disease scores (CDS). However, TC values affect the final

DrugRepo score (higher structural similarity corresponds to higher DrugRepo scores) as shown in **Figures 5C** and **5D**. Matched compounds for most the cancer types have median CDS >=0.7, showing the importance of CDS in defining DrugRepo (**Figure 5E** and **5F**). Median of OCTS for different cancer types is lower (0.1-0.5) than CDS, because complete target profiles (across full druggable genome) for most of the compounds is not experimentally tested. The average number of targets for candidate and approved compounds for each of the 5 databases is less than 7 [27]. However, we believe with the availability of additional high throughput DTI studies, distribution of OCTS in DrugRepo score may also increase.

Setting lower threshold on DrugRepo scores may result in more false positives (compounds not in clinical trials). So, we also analysed the proportion of hits across 10 thresholds on DrugRepo scores. As shown in **Figure 6**, with the increase in DrugRepo threshold reduces the risk of getting false positives. Especially hit percentage >=5% (for all cancers) at DrugRepo score >=0.4. However, having miss-hits with clinical trials does not necessarily mean false positive, as clinical trials has limited number of studies/compounds.




***Figure 6**. Hit ratio at different thresholds on different DrugRepo scores.The X axis shows thresholds on DrugRepo scores and Y axis shows the percentage of hits while matching with repurposed compounds at https://clinicaltrials.gov/*

Overall based on these successful matching, we can claim that DrugRepo score >= 0.4 might guarantee the repurposing of a candidate compound with less chances of false positives. There are not many compounds that have been tested at clinical trials, therefore we suggest top scoring compounds to be tested in-vitro to evaluate the significance of DrugRepo scores.

### 4.3.Using the DrugRepo's GUI to repurpose drugs for CML

Here, we provide a case study on Chronic Myeloid leukemia (CML) using the web interface at http://drugrepo.org/. DrugRepo has three approved drugs (imatinib, nilotinib, and bosutinib) for CML. Users may check one or more of these approved drugs and customize the structural similarity and DrugRepo thresholds as shown in **Figure 7A**. The top right space at DrugRepo shows database statistics and workflow diagram. The figure's section on DrugRepo displays the results for the selected disease and associated approved compounds. There are three figures that can be selected from the Figures dropdown list, i.e., 1) Statistics, 2) Repurposing scores, and 3) TSNE. The 'Statistics' displays the top targets (for approved drugs) and list of repurposing compounds (**Figure 7B**). We used standard InChIKey identifiers for the repurposing compounds instead of names because many of preclinical and investigational compounds haven't been assigned with proper names. For targets, we used UniProt IDs. The 'Repurposing scores' provides 3D scatterplot with x-axis as TC, y-axis as OCTS and z-axis as CDS scores. In the scatter plot, each point is a pair of approved drug and repurposed compounds. Repurposing compounds are assigned with colors similar to the most associated approved drug (**Figure 7C**). More details about diseases, approved drugs, repurposing compounds, and the three scores will show if users click on the scatter points. T-distributed stochastic neighbour embedding (TSNE) is used to visualize 2D similarity between approved drugs (purple) and repurposing compound (red) as shown in **Figure 7D**. The 2D similarity was computed based on ECFP4 fingerprints.

Down to the Figures, there is Tables section containing four tables as shown in 'Tables' dropdown list, 1) Drug repurposing table, 2) Approved drugs for the disease, 3) Disease-gene associations, and 4) Drug target profiles for drug and compounds. The 'Drug Repurposing' table provides four scores (TC, OCTS, CDS and DrugRepo) between approved and repurposing drugs. The 'Approved drugs for the disease' table displays UML-CUIs for the selected disease and standard InChIKeys of the approved drugs. The 'Disease-gene associations' table displays the genes associated with the selected disease. Finally, 'Drug target profiles for drug and compounds' table provides list of drug targets associated with the approved drugs and repurposing compounds. Users can take advantage from filter and sort options to customize the results and can download data for further analysis.




***Figure 7**: Using the DrugRepo GUI to repurpose drugs for CML. **(A)** Select disease interface, users can uncheck any of the approved drug, modify TC, and DrugRepo thresholds, **(B)** Top targets for approved drugs and top repurposing compounds, **(C)** Drug repurposing plot, each point is based on three scores for an approved drug and repurposing compound, **(D)** The 2D visualization for structural similarities between approved drugs and repurposing compounds*

## Conclusion

DrugRepo provides a platform for repurposing huge list of compounds using chemical and genomic features. We evaluated our methods by leveraging the datasets available at clinical trials and CTD. DrugRepo is based on three components i.e., structural similarity (TC), overlapping compound-target score (OCTS), and compound-disease scores (CDS). CDS (median ≥ 0.75 in nine cancer types) is based on PPI networks and found to be more effective than OCTS (median ≥ 0.3) for matching repurposed compounds (as shown **Figure 5G, 5H**). By matching repurposed compounds, we suggest DrugRepo score >=0.4 as the threshold to repurpose compounds for a selected disease as it has lower chances of having false positives (**Figure 6**). Computational analysis is further supported by web application (http://drugrepo.org/), where users can select a particular disease and obtain repurposed compounds along with other parameters. Using DrugRepo GUI, users can select a particular disease, check the approved drugs, targets associated with approved drugs or candidate compounds, and finally download the compounds that can be repurposed for the selected disease. Users can adjust thresholds for structural similarity (TC) and DrugRepo scores (TC) as shown in **Figure 7A**. We also provide user-friendly visualization by which users can apply

different filters to obtain specific results, and finally download results for further analysis. The web application is useful to design new drug repurposing applications as well as using existing information for the predictive analysis.

However, our method has some limitations. For instance, proposed approach is dependent on OCTS between approved drugs and candidate compounds. Missing data in DTI profiles for an approved drug or candidate compound may cause failure in capturing some of the important repurposing candidates. Although we integrated DTI profiles from five most comprehensive databases but still the average number of targets for approved drugs is around seven, which is much less than expected (as druggable targets are around 1000). However, new releases of DTI databases (such as ChEMBL, DrugBank or BindingDB) may bring additional curated DTIs, resulting in better repurposing applications. We will keep DrugRepo updated with the newly curated datasets to make it more effective. Presently DrugRepo is based only on three components. However, with the addition of more components (such as gene expression data), results can be further improved. We will therefore incorporate these improvements in the next version of DrugRepo.

**DECLARATIONS**

**Availability of data and material:** DrugRepo is available at http://drugrepo.org/.

**Competing interests:** Authors have financial competing interests.

**Funding:** This work was supported by the EU H2020 (EOSC-LIFE, No. 824087), the European Research Council (DrugComb, No. 716063) and the Academy of Finland (No. 317680).

**Authors' contributions:** Conceptualization: Z.T, J.T; Methodology: Z.T, Y.W; Software: Y.W, J.A, Y.H; Formal analysis: Y.W, H.Y, Z.T; Writing: J.T, Z.T, Y.W; Review & Editing: M.V; Supervision: J.T, Z.T

**Acknowledgements:** We thank CSC, Finland for providing us the IT services.

## REFERENCES

[1] Dickson, M.; Gagnon, J. P. The Cost of New Drug Discovery and Development. *Discov. Med.*, **2009**, *4* (22), 172–179.

[2] Shaughnessy, A. F. Old Drugs, New Tricks. *BMJ*, **2011**, *342*, d741.

[3] Pushpakom, S.; Iorio, F.; Eyers, P. A.; Escott, K. J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; et al. Drug Repurposing: Progress, Challenges and Recommendations. *Nat. Rev. Drug Discov.*, **2019**, *18* (1), 41–58. https://doi.org/10.1038/nrd.2018.168.

[4] Gupta, S. C.; Sung, B.; Prasad, S.; Webb, L. J.; Aggarwal, B. B. Cancer Drug Discovery by Repurposing: Teaching New Tricks to Old Dogs. *Trends in Pharmacological Sciences*. September 2013, pp 508–517. https://doi.org/10.1016/j.tips.2013.06.005.

[5] Lotfi Shahreza, M.; Ghadiri, N.; Mousavi, S. R.; Varshosaz, J.; Green, J. R. A Review of Network-Based Approaches to Drug Repositioning. *Brief. Bioinform.*, **2017**, *19* (5), 878–892.

[6] Zhao, K.; So, H.-C. Using Drug Expression Profiles and Machine Learning Approach for Drug Repurposing. In *Computational methods for drug repurposing*; Springer, 2019; pp 219–237.

[7] Tanoli, Z.; Vähä-Koskela, M.; Aittokallio, T. Artificial Intelligence, Machine Learning and Drug Repurposing in Cancer. *Expert Opin. Drug Discov.*, **2021**.

[8] Corsello, S. M.; Bittker, J. A.; Liu, Z.; Gould, J.; McCarren, P.; Hirschman, J. E.; Johnston, S. E.; Vrcic, A.; Wong, B.; Khan, M. The Drug Repurposing Hub: A next-Generation Drug Library and Information Resource. *Nat. Med.*, **2017**, *23* (4), 405–408.

[9] Brown, A. S.; Patel, C. J. A Standard Database for Drug Repositioning. *Sci. Data*, **2017**, *4*. https://doi.org/10.1038/sdata.2017.29.

[10] Shameer, K.; Glicksberg, B. S.; Hodos, R.; Johnson, K. W.; Badgeley, M. A.; Readhead, B.; Tomlinson, M. S.; O'Connor, T.; Miotto, R.; Kidd, B. A. Systematic Analyses of Drugs and Disease Indications in RepurposeDB Reveal Pharmacological, Biological and Epidemiological Factors Influencing Drug Repositioning. *Brief. Bioinform.*, **2018**, *19* (4), 656–678.

[11] Tanoli, Z.; Seemab, U.; Scherer, A.; Wennerberg, K.; Tang, J.; Vähä-Koskela, M. Exploration of Databases and Methods Supporting Drug Repurposing: A Comprehensive Survey. *Brief. Bioinform.*, **2020**.

[12] Mendez, D.; Gaulton, A.; Bento, A. P.; Chambers, J.; De Veij, M.; Félix, E.; Magariños, M. P.; Mosquera, J. F.; Mutowo, P.; Nowotka, M. ChEMBL: Towards Direct Deposition of Bioassay Data. *Nucleic Acids Res.*, **2019**, *47* (D1), D930–D940.

[13] Cichońska, A.; Ravikumar, B.; Allaway, R. J.; Wan, F.; Park, S.; Isayev, O.; Li, S.; Mason, M.; Lamb, A.; Tanoli, Z.; et al. Crowdsourced Mapping of Unexplored Target Space of Kinase Inhibitors. *Nat. Commun.*, **2021**, *12* (1), 3307. https://doi.org/10.1038/s41467-021-23165-1.

[14] Cichonska, A.; Rousu, J.; Aittokallio, T. Identification of Drug Candidates and Repurposing Opportunities through Compound–Target Interaction Networks. *Expert Opin. Drug Discov.*, **2015**, *10* (12), 1333–1345.

[15] Beck, B. R.; Shin, B.; Choi, Y.; Park, S.; Kang, K. Predicting Commercially Available Antiviral Drugs That May Act on the Novel Coronavirus (SARS-CoV-2) through a Drug-Target Interaction Deep Learning Model. *Comput. Struct. Biotechnol. J.*, **2020**, *18*, 784–790. https://doi.org/10.1016/j.csbj.2020.03.025.

[16] Davis, A. P.; Grondin, C. J.; Johnson, R. J.; Sciaky, D.; Wiegers, J.; Wiegers, T. C.; Mattingly, C. J. Comparative Toxicogenomics Database (CTD): Update 2021. *Nucleic Acids Res.*, **2021**, *49* (D1), D1138–D1143.

[17] Piñero, J.; Bravo, À.; Queralt-Rosinach, N.; Gutiérrez-Sacristán, A.; Deu-Pons, J.; Centeno, E.; García-García, J.; Sanz, F.; Furlong, L. I. DisGeNET: A Comprehensive Platform Integrating Information on Human Disease-Associated Genes and Variants. *Nucleic Acids Res.*, **2017**, *45* (D1), D833–D839.

[18] Gaulton, A.; Hersey, A.; Nowotka, M.; Bento, A. P.; Chambers, J.; Mendez, D.; Mutowo, P.; Atkinson, F.; Bellis, L. J.; Cibrián-Uhalte, E.; et al. The ChEMBL Database in 2017. *Nucleic Acids Res.*, **2016**, *45* (D1), D945–D954.

[19] Gilson, M. K.; Liu, T.; Baitaluk, M.; Nicola, G.; Hwang, L.; Chong, J.; Al., E. BindingDB in 2015: A Public Database for Medicinal Chemistry, Computational Chemistry and Systems Pharmacology. *Nucleic Acids Res.*, **2016**, *44* (D1), D1045–D1053.

[20] Alexander, S. P. H.; Kelly, E.; Marrion, N. V; Peters, J. A.; Faccenda, E.; Harding, S. D.; Pawson, A. J.; Sharman, J. L.; Southan, C.; Buneman, O. P. The Concise Guide to PHARMACOLOGY 2017/18: Overview. *Br. J. Pharmacol.*, **2017**, *174* (S1).

[21] Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.;

Chang, Z.; Woolsey, J. DrugBank: A Comprehensive Resource for in Silico Drug Discovery and Exploration. *Nucleic Acids Res.*, **2006**, *34*, D668–D672.

[22] Wagner, A. H.; Coffman, A. C.; Ainscough, B. J.; Spies, N. C.; Skidmore, Z. L.; Campbell, K. M.; Krysiak, K.; Pan, D.; McMichael, J. F.; Eldred, J. M. DGIdb 2.0: Mining Clinically Relevant Drug–Gene Interactions. *Nucleic Acids Res.*, **2015**, gkv1165.

[23] Chambers, J.; Davies, M.; Gaulton, A.; Hersey, A.; Velankar, S.; Petryszak, R.; Hastings, J.; Bellis, L.; McGlinchey, S.; Overington, J. P. UniChem: A Unified Chemical Structure Cross-Referencing and Identifier Tracking System. *J. Cheminform.*, **2013**, *5* (1).

[24] Wang, Y.; Bryant, S. H.; Cheng, T.; Wang, J.; Gindulyte, A.; Shoemaker, B. A.; Thiessen, P. A.; He, S.; Zhang, J. PubChem BioAssay: 2017 Update. *Nucleic Acids Res.*, **2016**, *45* (D1), D955–D963.

[25] Consortium, U. UniProt: A Hub for Protein Information. *Nucleic Acids Res.*, **2014**, *43* (D1), D204–D212.

[26] Tang, J.; Tanoli, Z.-R.; Ravikumar, B.; Alam, Z.; Rebane, A.; Vähä-Koskela, M.; Peddinti, G.; van Adrichem, A. J.; Wakkinen, J.; Jaiswal, A.; et al. Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. *Cell Chem. Biol.*, **2018**, *25* (2), 224–229. https://doi.org/doi:10.1016/J.CHEMBIOL.2017.11.009.

[27] Tanoli, Z.; Aldahdooh, J.; Alam, F.; Wang, Y.; Seemab, U.; Fratelli, M.; Pavlis, P.; Hajduch, M.; Bietrix, F.; Gribbon, P.; et al. Minimal Information for Chemosensitivity Assays (MICHA): A next-Generation Pipeline to Enable the FAIRification of Drug Screening Experiments. *Brief. Bioinform.*, **2021**. https://doi.org/10.1093/bib/bbab350.

[28] Cheng, F.; Kovács, I. A.; Barabási, A.-L. Network-Based Prediction of Drug Combinations. *Nat. Commun.*, **2019**, *10* (1), 1197. https://doi.org/10.1038/s41467-019-09186-x.